The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Helicobacter pylori Eradication Rates among Patients Undergoing Endoscopy Remain Stagnant Despite Evolving Clinical Practice Patterns

Authors: Caroline Labriola, MD, Priya Alagesan, MD, HannahSofia Brown, MD, Frances Wang, MS, Terry Hyslop, PhD, Rachel Zuzul, MD, Grace Sekaya, BS, Meira Epplein, PhD, Katherine S. Garman, MD

Abstract

Objectives: Helicobacter pylori is the strongest risk factor for non-cardia gastric adenocarcinoma, the cancer with the greatest racial disparity in US cancer mortality. The 2017 American College of Gastroenterology guidelines recognized that local H pylori antibiotic resistance data are often unavailable in the United States, highlighted increasing clarithromycin resistance, and recommended that providers review previous antibiotic exposures before selection of an H pylori treatment regimen.

Methods: We analyzed a retrospective cohort of 477 patients with H pylori diagnosed on upper endoscopy (or esophagogastroduodenoscopy [EGD]) from 2015 to 2019. Clinical data abstracted included all EGD findings, H pylori diagnoses, treatments, eradication testing, and prior macrolide and metronidazole exposures.

Results: Overall, eradication testing rates were low after index EGD, with 50% of the 477 patients receiving eradication testing after H pylori diagnosis although eradication testing rates increased from 35% in 2015 to 64% in 2019 (P < 0.0001). During this time period, H pylori treatment practice patterns shifted from triple to quadruple therapy without a corresponding increase in successful eradication, and overall, successful eradication was achieved in 72% of patients. After an initial H pylori diagnosis, 202 patients were treated, followed by completion of eradication testing. We found no significant differences in eradication rates based on prior antibiotic exposures; comparing H pylori eradication rates for previous macrolide treated with clarithromycin (85%), previous metronidazole treated with metronidazole (73%) versus no prior antibiotic exposure (86%).

Conclusions: Although guidelines suggest querying prior antibiotic exposures before selecting H pylori therapy, our findings emphasize that alternative methods to improve eradication rates may be important. Although practice patterns shifted to use more metronidazole-based therapy, as currently suggested as first-line H pylori therapy in the United States, this change was not associated with an overall improvement in eradication rates.
Posted in: Gastroenterology57

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347(15): 1175–1186.
 
2. Plummer M, Franceschi S, Vignat J, et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015;136(2):487–490.
 
3. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017;153(2):420–429.
 
4. Epplein M, Signorello LB, Zheng W, et al. Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev 2011;20(5):826–834. .
 
5. Chen YC, Malfertheiner P, Yu HT, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology 2024;166(4): 605–619.
 
6. Brown H, Cantrell S, Tang H, Epplein M, Garman KS. Racial Differences in Helicobacter pylori Prevalence in the US: A Systematic Review. Gastro Hep Adv 2022;1(5):857–868.
 
7. Shah SC, Halvorson AE, Lee D, et al. Helicobacter pylori burden in the United States according to individual demographics and geography: a nationwide analysis of the Veterans Healthcare System. Clin Gastroenterol Hepatol. 2024; 22(1):42–50.
 
8. Collaborators Global Burden of Disease US Health Disparities Collaborators. The burden of stomach cancer mortality by county, race, and ethnicity in the USA, 2000-2019: A systematic analysis of health disparities. Lancet Reg Health Am 2023;24:100547.
 
9. Lee YC, Chiang TH, Chou CK, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 2016;150(5):1113–1124.
 
10. Li D, Jiang SF, Lei NY, Shah SC, Corley DA. Effect of Helicobacter pylori Eradication Therapy on the Incidence of Noncardia Gastric Adenocarcinoma in a Large Diverse Population in the United States. Gastroenterology 2023;165(2):391–401.
 
11. Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 2020;69(12):2113–2121.
 
12. Hung KW, Maratt JK, Cho WK, et al. AGA Institute Quality Measure Development for the Management of Gastric Intestinal Metaplasia With Helicobacter pylori. Gastroenterology 2022;163(1):3–7.
 
13. Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017;112(2):212–239.
 
14. Chey WD, Howden CW, Moss SF, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 2024;119:1730–1753.
 
15. Harris A. Treatment of Helicobacter pylori. World J Gastroenterol 2001;7(3):303–307.
 
16. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015;6(4):183–198.
 
17. Boltin D, Levi Z, Gingold-Belfer R, et al. Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success. J Clin Gastroenterol 2020;54(4):333–337.
 
18. Boltin D, Levi Z, Gingold-Belfer R, et al. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. Am J Gastroenterol 2019; 114(6):900–906.
 
19. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62(1):34–42.
 
20. Zhao F, Wang J, Yang Y, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 2008;13(6):532–541.
 
21. White B, Winte M, DeSipio J, Phadtare S. Clinical Factors Implicated in AntibioticResistance in Helicobacter pylori Patients. Microorganisms 2022;10(2):322.
 
22. Lim SG, Park RW, Shin SJ, et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis 2016;48(4):385–390.
 
23. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004;10(6): 1088–1094.
 
24. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018;155(5):1372–1382.
 
25. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19(4):409–414.
 
26. Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014;20(18):5252–5262.
 
27. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014;14(8):742–750.
 
28. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53(9):1374–1384.
 
29. Moss SF. How can we rationally select Helicobacter pylori therapy without resistance data? Clin Gastroenterol Hepatol 2014;12(9):1578.
 
30. Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021;160(5): 1831–1841.
 
31. Zamani M, Alizadeh-Tabari S, Zamani V, et al. Worldwide and Regional Efficacy Estimates of First-line Helicobacter pylori Treatments: A Systematic Review and Network Meta-Analysis. J Clin Gastroenterol 2022;56(2):114–124.
 
32. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997;41(1):8–13.
 
33. Pohl D, Keller PM, Bordier V, et al. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J Gastroenterol 2019;25(32):4629–4660.
 
34. Ho JJC, Navarro M, Sawyer K, et al. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2022;117(8):1221–1230.
 
35. Megraud F, Graham DY, Howden CW, et al. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol 2023;118(2):269–275.
 
36. Epplein M, McCall S, Wang F, et al. Prevalence of the cagA Virulence Factor Varies byRace among H. pylori-infected Patients Undergoing Upper Endoscopy. Clin Transl Gastroenterol 2024;15(6):e1.
 
37. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2):377–381.
 
38. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208.
 
39. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373–383.
 
40. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173(6):676–682.
 
41. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012;61(5):646–664.
 
42. Feder R, Posner S, Qin Y, et al. Helicobacter pylori-associated peptic ulcer disease: A retrospective analysis of post-treatment testing practices. Helicobacter 2018;23(6):e12540.
 
43. Kumar S, Metz DC, Kaplan DE, et al. Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration. Clin Gastroenterol Hepatol 2021;19(2):305–313.
 
44. Epplein M, Cohen SS, Sonderman JS, et al. Neighborhood socio-economic characteristics, African ancestry, and Helicobacter pylori sero-prevalence. Cancer Causes Control 2012; 23(6):897–906.
 
45. Everhart JE, Kruszon-Moran D, Perez-Perez GI, et al. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000;181(4):1359–1363.
 
46. Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol 2012;175(1):54–59.
 
47. Varga MG, Butt J, Blot WJ, et al. Racial Differences in Helicobacter pylori CagA Seroprevalence in a Consortium of Adult Cohorts in the United States. Cancer Epidemiol Biomarkers Prev 2020;29(10):2084–2092.
 
48. Nguyen T, Ramsey D, Graham D, et al. The Prevalence of Helicobacter pylori Remains High in African American and Hispanic Veterans. Helicobacter 2015;20(4):305–315.
 
49. Horie R, Handa O, Ando T, et al. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan. Helicobacter 2020;25(4):e12698.
 
50. Graham DY, Moss SF. Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why. Am J Gastroenterol 2022;117(4):524–528.
 
51. Chen MJ, Chen PY, Fang YJ, et al. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials. Lancet Gastroenterol Hepatol 2023;8(7):623–634.
 
52. Bujanda L, Nyssen OP, Ramos J, et al. Effectiveness of Helicobacter pylori treatments according to antibiotic resistance. Am J Gastroenterol 2024;119(4):646–654.